Haichuang Pharmaceutical (688302.SH): HP568 tablets approved for clinical trials to treat ER+/HER2-advanced breast cancer

Zhitongcaijing · 10/15 10:17

Zhitong Financial App News, Haichuang Pharmaceutical (688302.SH) issued an announcement. Recently, the company received the “Drug Clinical Trial Approval Notice” approved and issued by the Drug Evaluation Center of the China National Drug Administration, agreeing to carry out HP568 tablets to treat advanced breast cancer (ER+ER2) positive and human epidermal growth factor receptor 2 (Human Epidermal Growth Factor Receptor, HER2) negative advanced breast cancer) clinical trial. According to inquiries, as of the disclosure date of this announcement, no similar PROTAC products at home or abroad have been approved for listing.

Preclinical study results showed that in vitro HP568 exerts its anti-proliferative activity by specifically catalyzing ERα rapid proteasome-dependent degradation. HP568 has strong degrading activity against ERα wild-type (WT) protein and clinically common ERα mutant proteins. In vivo mouse models, HP568 can inhibit the growth of mice in situ grafted tumors in a dose-dependent manner, and the drug safety is good. Based on the results of in vitro and vitro studies of HP568, it can be expected that HP568 is an effective treatment for ER+/HER2- breast cancer.